Vilamakitug

DB18978InvestigationalProtein Based Therapies

Vilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure...

Mechanism: Pharmacologically active on Interleukin-1 alpha
Curator reviewed
Also known as: Immunoglobulin g4, anti-(human interleukin 1.alpha.) (human monoclonal xb2001 .gamma.4-chain), disulfide with human monoclonal xb2001 .kappa.-chain, dimer · Natrunix
Code names: XB-2001

Resolves to

Compound

UNII3562YZ5W3HCAS2458202-06-5

Targets

P01583IL1A

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vilamakitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account